Eltrombopag
Eltrombopag
Eltrombopag (pronounced el-trom-boh-pag) is a medication used to treat thrombocytopenia, a condition characterized by a low platelet count in the blood.
Etymology
The name "Eltrombopag" is derived from elements of its chemical structure. "El" stands for Electron, "trombo" is derived from Thrombocyte, the scientific term for platelets, and "pag" is an abbreviation of the chemical group Phenylaminoglycoside.
Usage
Eltrombopag is primarily used to increase the number of platelets in the blood for adults and children over one year of age with a certain type of chronic immune (idiopathic) thrombocytopenic purpura (ITP). It is also used to treat people with chronic hepatitis C who are receiving antiviral treatment.
Mechanism of Action
Eltrombopag works by stimulating the bone marrow to produce more platelets. It does this by binding to the thrombopoietin receptor, which is a protein on the surface of cells in the bone marrow. This binding triggers the cells to produce and release more platelets into the blood.
Side Effects
Common side effects of Eltrombopag include nausea, diarrhea, and fatigue. Serious side effects may include liver damage and increased risk of blood clots.
Related Terms
- Thrombocytopenia
- Thrombocyte
- Phenylaminoglycoside
- Idiopathic Thrombocytopenic Purpura
- Chronic Hepatitis C
- Bone Marrow
- Thrombopoietin Receptor
- Nausea
- Diarrhea
- Fatigue
- Liver Damage
- Blood Clot
External links
- Medical encyclopedia article on Eltrombopag
- Wikipedia's article - Eltrombopag
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski